ML115

ML115, a molecular probe of the signal transducer, is a selective STAT3 agonist, with an EC50 of 2 nM. ML115 increases the expression of BCL3, a known STAT3-dependent oncogene. ML115 is inactive against the related STAT1, STAT5 and NF-κB anti-targets. ML115 counteracts the effects of Ginsenoside Rc (HY-N0042) on cell viability and inflammatory responses in LPS (HY-D1056) -stimulated H9c2 and RAW264.7 cells, while altering oxidative stress markers. ML115 can be used for the study of breast and prostate cancers[1][2].

Product Specifications

CAS Number

[912798-42-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ml115.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=NOC(C2CC2)=C1)NC3=CC(OC)=C(Cl)C=C3OC

Molecular Formula

C15H15ClN2O4

Molecular Weight

322.74

Precautions

H302, H315, H319, H335

References & Citations

[1]Jinzhong Wang MS, et al. STAT3/FoxO3a/Sirt1 pathway inhibition by ginsenoside Rc ameliorates cardiomyocyte damage in septic cardiomyopathy by altering macrophage polarization. J Mol Histol. 2025 Apr 28;56 (3) :148. |[2]Madoux F, et al. Modulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Activators) . 2009 Aug 27 [updated 2010 Dec 16]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD) : National Center for Biotechnology Information (US) ; 2010–.